Clinical Research Directory
Browse clinical research sites, groups, and studies.
Combined Immunosuppression for Pediatric Crohn's Disease
Sponsor: Children's Hospital of Fudan University
Summary
This is a randomized controlled trial to compare the efficacy and safety of infliximab and immunosuppressives therapy alone or in combination for pediatric Crohn's disease.
Official title: Combination Therapy of Infliximab and Immunosuppressives for Pediatric Crohn's Disease
Key Details
Gender
All
Age Range
6 Years - 18 Years
Study Type
INTERVENTIONAL
Enrollment
128
Start Date
2022-10-10
Completion Date
2026-12-31
Last Updated
2026-03-19
Healthy Volunteers
No
Interventions
Infliximab and immunosuppressives
the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks, the immunomodulatory agent was azathioprine 1-2mg/kg per day or methotrexate 10-25 mg/m2 week
Infliximab
the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks
Locations (1)
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, China